Korea Chorus Consortium Accelerates Production of 'Sputnik V' Vaccine

Russia's 'Sputnik V' vaccine
[Image source=Reuters Yonhap News]

[Asia Economy Reporter Chunhee Lee] Korea Chorus announced on the 26th that it has introduced bioreactors for the full-scale commercial production of the Russian sovereign wealth fund (RDIF)'s COVID-19 vaccine 'Sputnik V.'

A bioreactor is a machine used for culturing cells, and the Sputnik V vaccine, which utilizes an adenovirus vector, cultivates the virus through this equipment. The bioreactors being introduced this time are four 'full set' units with a capacity of 1000ℓ. All of these bioreactors were originally intended for use by Korea Chorus, but after RDIF, GL Rapha, and Korea Chorus agreed on an additional 500 million doses, some were provided to the consortium companies formed. A Korea Chorus official stated, "Since it takes time for consortium companies to purchase equipment, by proactively providing some of the introduced units, we aim to enhance the capabilities of the consortium companies and pursue the value of mutual growth."

Currently, the Korea Chorus consortium, with Isu Abxis having transferred technology, has been conducting pilot production procedures since the 19th. Technology transfer is also underway to other consortium member companies.

This content was produced with the assistance of AI translation services.